FDA’s evaluation of the safety of drug products often requires combining and summarizing information from multiple sources, and meta-analysis is a useful tool for this purpose. This document provides guidance on the use of meta-analyses of randomized controlled clinical trials (RCTs) to evaluate the safety of human drugs or biological products in the context of FDA’s regulatory decision-making. (fda.gov)